NIH COVID-19 Treatment Guidelines Panel Updates Position on Ivermectin

WHO Looking at Ivermectin within Weeks as COVID-19 for Early Onset Treatment

The National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel just updated their guidelines on ivermectin for COVID-19. Essentially the same guidance as their interim guidance posted last month, a couple weeks past their meeting with the leaders of the Front Line COVID-19 Critical Care Alliance (FLCCC) and Dr. Andrew Hill affiliated with the University of Liverpool. However, they included more information. Now the apex research body panel introduces a handful of studies for the record. Of note, they did manage to select some of the worst outcome studies of the many that are the basis for both the FLCCC and Dr. Andrew Hill’s meta-analyses. While the FLCCC meta-analysis includes 16 ranomzied controlled ivermectin trials (13 treatment and 3 prophylaxis) Dr. Andrew HIll's effort includes 22 randomized trials and approaches 3,000 patients. Both the FLCCC and Dr. Hill presented 17 randomized controlled ivermectin studies to the prominent Panel in early January. Apparently, not all of these impressed the NIH's Panel as they included only 7 such randomized studies and interestingly they made a point to reference one of the worst performing studies globally out of Peru—a retr...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee